Browse the evidence

Patients with Obstructive Sleep Apnea (OSA) face a significantly increased risk of major perisurgical adverse outcomes and perioperative death when undergoing bariatric surgery.

Having sleep apnea makes weight loss surgery much more dangerous. It triples your risk of dying during the procedure. This is why doctors require a sleep study before surgery.

Tobacco smoking and high blood pressure are the leading preventable causes of death in the United States, responsible for approximately 467,000 and 395,000 deaths respectively in 2005.

Stop smoking and manage your blood pressure. These two factors alone account for roughly 20% of all adult deaths in the US. Effective interventions exist for both, making them the highest-impact targets for improving longevity and health.

Genetic disruption of core clock genes (e.g., Clock, Bmal1, Per) in mice leads to obesity, hyperphagia, and metabolic disorders, demonstrating a direct genetic link between circadian regulation and energy homeostasis.

Understand that your genetics play a role in how your body handles time and food. If you have a family history of metabolic issues, strict adherence to circadian hygiene (regular sleep/eating times) may be even more critical for you.

Accurate dietary assessment using Food Frequency Questionnaires (FFQs) is insufficient for studying diet-microbiome relationships because they lack the specificity to link specific foods to microbial changes.

Most large-scale diet studies use simple questionnaires that may not accurately reflect what you ate. For microbiome research, these methods are often too vague to find specific links between foods and bacteria. More detailed food records are needed for accurate results.

Peptide 20, a GIPR/GLP-1R/GCGR tri-agonist, achieves balanced potency across all three receptors through specific structural modifications, including lipidation of K10P, which stabilizes binding and enhances receptor-mediated cAMP accumulation.

Peptide 20 is a complex drug that activates three metabolic receptors (GIP, GLP-1, Glucagon) simultaneously. Its effectiveness relies on specific chemical modifications (lipidation) that stabilize the drug's binding to these receptors, leading to significant improvements in blood sugar, weight, and glucose tolerance in animal models.

The unilateral exercise model (training one limb while keeping the contralateral limb as a control) significantly increases statistical power and reduces study costs compared to parallel-group or standard crossover designs by eliminating inter-subject variability and the need for washout periods.

For researchers, using a unilateral exercise model (training one limb while keeping the other as a control) is a highly efficient way to study muscle adaptations. It allows you to use fewer participants, reduces costs (fewer biopsies, less food provision), and eliminates the need for long washout periods between treatments, provided you are studying biochemical or histological outcomes rather than systemic or neuromuscular strength transfers.

The exact energy cost of skeletal muscle hypertrophy is unknown, and common textbook estimates based solely on tissue composition are likely inaccurate because they ignore the metabolic costs of synthesis, exercise, and adaptive thermogenesis.

Do not rely on textbook calculations for the exact energy cost of muscle gain. These estimates are likely inaccurate. Instead, use a conservative surplus (1,500-2,000 kJ/day) and adjust based on your progress. Individual responses vary greatly due to genetics and metabolic adaptations.

Glucagon emergency kits (subcutaneous, intramuscular, or intranasal) are the standard of care for rapidly reversing severe hypoglycaemia in Type 1 Diabetes, with newer formulations offering faster resolution and ease of use.

If you have Type 1 Diabetes, keep a glucagon emergency kit (like Baqsimi or Zegalogue) accessible. In a severe low blood sugar emergency where the person cannot eat or drink, this medication rapidly raises blood sugar by signaling the liver to release glucose. Newer nasal and auto-injector versions are easier to use and work faster than older injection kits.

Bariatric/metabolic surgery (BMS) is the most effective strategy for significant and sustained body weight reduction (14-25%) and reduces the risk of hypertension, diabetes, and mortality, but remains underused.

For extreme obesity (BMI ≥ 40 or ≥ 35 with comorbidities), bariatric surgery is the most effective treatment, producing 14-25% weight loss and significantly reducing the risk of heart disease, diabetes, and death. Despite its effectiveness, it is underused. If lifestyle and medication fail, discuss surgery with your doctor as a viable, life-saving option.

Leptin signaling via hypothalamic LepRbGlp1r neurons is the primary driver of food intake suppression, as ablating this receptor causes hyperphagic obesity without impairing energy expenditure.

This research identifies a specific brain pathway (LepRbGlp1r neurons) that leptin uses to tell you to stop eating. When this pathway is broken or ignored, you eat more regardless of how much energy you burn. This explains why some obesity treatments focus on mimicking these signals (like GLP-1 drugs) to restore the 'stop eating' signal rather than just forcing exercise.

Bariatric surgery is currently the most effective treatment for obesity in terms of mortality reduction and comorbidity resolution, but it is restricted to higher BMI classes and not suitable for all patients.

Bariatric surgery is the most effective treatment for obesity, significantly reducing mortality and type 2 diabetes risk, but it is generally reserved for patients with Class II or III obesity (BMI ≥ 35 or ≥ 40) and is not suitable for everyone due to surgical risks and access issues.

SGLT2 inhibitors provide significant cardiovascular and renal protection in patients with type 2 diabetes, heart failure, and chronic kidney disease, independent of glycemic control.

If you have Type 2 Diabetes along with heart failure or kidney disease, SGLT2 inhibitors (like Jardiance, Farxiga, or Trulicity's cousin) are now a standard, first-line treatment. They protect your heart and kidneys regardless of your blood sugar numbers. Discuss starting one with your doctor immediately, as guidelines strongly recommend it for this specific patient profile.

Tobacco smoking and high blood pressure are the leading preventable causes of death in the US, responsible for approximately 467,000 and 395,000 deaths respectively in 2005.

Focus on controlling blood pressure and avoiding tobacco as the highest-impact actions for longevity. These two factors alone account for roughly 20% of all adult deaths in the US, surpassing the combined impact of most dietary risks.

Sodium glucose cotransporter 2 inhibitors (SGLT2i) significantly reduce the composite risk of cardiovascular death or heart failure hospitalization in patients with heart failure with preserved ejection fraction (HFpEF), regardless of diabetes status.

If you have HFpEF, ask your doctor about SGLT2 inhibitors (like empagliflozin or dapagliflozin). These drugs are proven to reduce the risk of heart failure hospitalization and cardiovascular death, even if you do not have diabetes. They are a standard part of modern treatment.

GLP-2 analogs are effectively used in the management of short bowel syndrome, reducing the need for parenteral support and improving patient quality of life.

For patients with short bowel syndrome, GLP-2 analogs are an effective treatment that can reduce the need for intravenous nutrition (parenteral support) and improve quality of life.

Glucagon remains essential for emergency hypoglycemia treatment.

Glucagon is an essential emergency treatment for severe hypoglycemia. Patients at risk should have access to glucagon kits and be trained in their use to ensure rapid and effective treatment of low blood sugar episodes.

Current food environment policies in Vietnam are insufficient, with 74% of assessed indicators scoring low or very low, particularly in food composition standards, marketing, and labeling.

Policymakers must move beyond food safety regulations to address nutritional quality. This requires implementing mandatory food composition standards (e.g., sugar/salt/trans-fat limits), restricting marketing of unhealthy foods (especially to children), and enforcing front-of-package labeling.

Intensive glycemic control (targeting HbA1c ≤ 6.5%) does not significantly reduce cardiovascular events or all-cause mortality in patients with Type 2 Diabetes compared to standard control, and may increase mortality risk.

If you have Type 2 Diabetes, aiming for extremely low blood sugar (like an A1c under 6.5%) may not protect your heart and could actually increase your risk of death or severe low-blood-sugar episodes. Focus on standard control targets (around 7%) and managing blood pressure and cholesterol instead, unless your doctor advises otherwise based on your specific health history.

Intensive blood pressure control (targeting systolic BP < 120 mmHg) does not reduce fatal or nonfatal major cardiovascular events in patients with Type 2 Diabetes compared to standard control (< 140 mmHg) and increases adverse events.

If you have Type 2 Diabetes and high blood pressure, aiming for very low blood pressure (under 120 systolic) does not protect your heart more than standard targets (under 140) and may cause side effects like dizziness or kidney issues. Stick to standard guidelines unless your doctor specifies otherwise.

High-dose omega-3 carboxylic acid formulation (4 g/d) does not reduce major adverse cardiovascular events in high-risk patients with atherogenic dyslipidemia compared to corn oil.

For high-risk patients with high triglycerides and low HDL, adding 4g/day of omega-3 carboxylic acid to statin therapy does not reduce the risk of heart attack, stroke, or cardiovascular death compared to a placebo. This specific formulation and dose should not be relied upon for cardiovascular risk reduction in this population.

There is no significant interaction between FTO genetic variants and dietary intake (total energy, protein, carbohydrate, or fat) on Body Mass Index (BMI).

Having the FTO obesity gene does not mean you need a special diet. This study shows that whether you eat high or low carb, high or low fat, your BMI response to these diets is not significantly different from non-carriers. Focus on sustainable, balanced eating rather than trying to match a specific macronutrient profile to your genetics.

Empagliflozin (10 mg/day) does not significantly reduce the primary composite endpoint of hospitalization for heart failure or death from any cause in patients hospitalized with acute myocardial infarction.

Empagliflozin (10 mg daily) did not significantly reduce the risk of heart failure hospitalization or death in patients recently hospitalized for a heart attack, according to the EMPACT-MI trial. However, secondary analyses suggested some benefits in reducing heart failure events.

Overexpression of caveolin-1 in adipocytes increases caveolae density, enhances insulin-stimulated glucose uptake, and allows for larger lipid droplet storage.

This paper explains the cellular machinery behind fat storage. High levels of caveolin-1 help fat cells store more fat and process glucose better. This is a biological mechanism, not a direct advice for humans to manipulate, but it explains why some people store fat more easily than others.

A 12-week treatment with dulaglutide (1.5 mg weekly) does not improve long-term smoking abstinence rates compared to placebo when used as an adjunct to standard cessation therapy.

If you are trying to quit smoking, taking dulaglutide (Trulicity) alongside standard treatment (like Chantix/varenicline) will not increase your chances of staying smoke-free compared to standard treatment alone. Do not expect dulaglutide to help you quit smoking.